Great Lakes Gastroenterology Research, LLC

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Crohn's disease6 trials
• Ulcerative colitis6 trials
• Coeliac disease2 trials
• Irritable bowel syndrome1 trial

Phase

• Phase 36 trials
• Phase 24 trials
• Phase 42 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Recruiting7 trials
• Active, not recruiting4 trials
• Completed2 trials
• Terminated2 trials

Lead sponsor

• Janssen Research & Development, LLC5 trials
• Takeda3 trials
• Alfasigma S.p.A.1 trial
• Chugai Pharmaceutical1 trial
• CinPhloro Pharma, LLC1 trial
• and 4 more

Running trials

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population

  NCT07623902· Jubaan Ltd.· Source

  Contact: Christy DeJohn

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of DONQ52 in Active Celiac Disease

  NCT07239336· Phase 2· Chugai Pharmaceutical· Source

• Recruiting

  A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  NCT06581328· Phase 4· Takeda· Source

  Contact: Keith Friedenberg (principal investigator)

• Active, not recruiting

  A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  NCT06045754· Phase 4· Takeda· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Takeda· Source

  Contact: Keith Friedenberg (principal investigator)

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease4 recruiting
• Ulcerative colitis2 recruiting
• Coeliac disease1 recruiting

Closed trials

• Terminated

  Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

  NCT06153420· Phase 2· CinPhloro Pharma, LLC· Source

• Terminated

  A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

  NCT05574010· Phase 1/2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Completed

  Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

  NCT04469686· Phase 3· Cristcot HCA LLC· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source